Tricida to Present at the 39th Annual J.P. Morgan Healthcare Conference
Tricida, Inc. (Nasdaq: TCDA) will present at the 39th Annual J.P.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Tricida, Inc. (Nasdaq: TCDA) will present at the 39th Annual J.P. Morgan Healthcare Conference on January 13, 2021, at 11:50 am PT / 2:50 pm ET. CEO Gerrit Klaerner will discuss the company's overview and key initiatives. Investors can access a live webcast on the Tricida website, with an archived version available for 90 days post-presentation. Tricida focuses on developing veverimer (TRC101), an investigational drug for treating metabolic acidosis in chronic kidney disease (CKD) patients, which affects approximately three million individuals in the U.S.
Details
News Market Reaction – TCDA
The recorded move for TCDA in the trading session of this news was +4.21%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
SOUTH SAN FRANCISCO, Calif., Jan. 06, 2021 (GLOBE NEWSWIRE) -- Tricida, Inc. (Nasdaq: TCDA) today announced that it will present at the 39th Annual J.P. Morgan Healthcare Conference on Wednesday, January 13, 2021 at 11:50 am PT / 2:50 pm ET. Gerrit Klaerner, Ph.D., Tricida’s Founder, President and CEO, will provide a company overview, business update and progress on the company’s key initiatives.
A live webcast of the presentation will be accessible on the Tricida website at IR.Tricida.com. An archive of the webcast will be available for 90 days following the presentation.
About Tricida
Tricida, Inc. is a pharmaceutical company focused on the development and commercialization of its investigational drug candidate, veverimer (TRC101), a non-absorbed, orally-administered polymer designed to treat metabolic acidosis in patients with CKD. There are no FDA-approved treatments for chronic metabolic acidosis, a condition commonly caused by CKD that is believed to accelerate the progression of kidney deterioration. It is estimated to pose a health risk to approximately three million patients with CKD in the United States.
For more information about Tricida, please visit www.Tricida.com.
Contact:
Jackie Cossmon, IRC
Tricida, Inc.
Senior Vice President of Investor Relations and Communications
IR@Tricida.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.